logo-loader

Allergy Therapeutics to sniff out more M&A deals, says CEO

Published: 10:14 21 Sep 2015 EDT

Manuel Llobert, chief executive of Allergy Therapeutics (LON:AGY), says the firm is far better placed to make acquisitions given the recent increase in its market value.

Shares in the allergy prevention are specialist up 28% in the last six months and Llobert says the company will likely add to its purchase of Spain’s Alerpharma earlier this year.

It comes as revenues from the maker of the Pollinex range of vaccines rose by 11% to £46.6mln in the year to June.

The rise, according to the CEO, is down to a “well-accepted portfolio” containing the “most convenient products" in the market.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

40 minutes ago